[go: up one dir, main page]

ES2122555T3 - Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos. - Google Patents

Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.

Info

Publication number
ES2122555T3
ES2122555T3 ES95910164T ES95910164T ES2122555T3 ES 2122555 T3 ES2122555 T3 ES 2122555T3 ES 95910164 T ES95910164 T ES 95910164T ES 95910164 T ES95910164 T ES 95910164T ES 2122555 T3 ES2122555 T3 ES 2122555T3
Authority
ES
Spain
Prior art keywords
new
estrogens
disorders related
derivatives useful
neoplasms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910164T
Other languages
English (en)
Inventor
Alan J Bitonti
Ian A Mcdonald
Francesco G Salituro
Jeffrey P Whitten
Esa T Jarvi
Paul S Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2122555T3 publication Critical patent/ES2122555T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/281-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

NUEVOS DERIVADOS INDOLICOS UTILES PARA TRATAR NEOPLASMAS Y TRASTORNOS RELACIONADOS CON ESTROGENOS. LA PRESENTE INVENCION SE REFIERE A NUEVOS DERIVADOS DE INDOL DE FORMULA (I), UTILES EN EXPRESION DE RECEPTOR DE ESTROGENO DE REGULACION BAJA. TAMBIEN SE INCLUYEN METODOS PARA EL TRATAMIENTO DE NEOPLASMAS O PARA EL CONTROL DEL CRECIMIENTO DE UN NEOPLASMA EN UN PACIENTE AQUEJADO CON UNA ENFERMEDAD NEOPLASTICA, ESPECIALMENTE NEOPLASMAS NECESITADOS DE ESTROGENOS ASI COMO ESOS ASOCIADOS CON TEJIDO DEL PECHO, OVARICO Y CERVICAL. OTRA VERSION DE LA PRESENTE INVENCION ES UN METODO PARA TRATAR PROFILACTICAMENTE A UN PACIENTE EN RIESGO A DESARROLLAR UN ESTADO DE ENFERMEDAD NEOPLASTICA. TAMBIEN SE PROPORCIONA UN METODO PARA TRATAR ENFERMEDADES AUTOINMUNES. TAMBIEN SE INCLUYEN COMPOSICIONES FARMACEUTICAS DE LOS NUEVOS DERIVADOS DE INDOL.
ES95910164T 1994-02-22 1995-01-31 Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos. Expired - Lifetime ES2122555T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20005794A 1994-02-22 1994-02-22
US36204694A 1994-12-22 1994-12-22

Publications (1)

Publication Number Publication Date
ES2122555T3 true ES2122555T3 (es) 1998-12-16

Family

ID=26895427

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910164T Expired - Lifetime ES2122555T3 (es) 1994-02-22 1995-01-31 Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.

Country Status (17)

Country Link
US (1) US5877202A (es)
EP (1) EP0746544B1 (es)
JP (1) JP3536258B2 (es)
KR (1) KR100362864B1 (es)
CN (1) CN1141627A (es)
AT (1) ATE170839T1 (es)
AU (1) AU680740B2 (es)
CA (1) CA2183731C (es)
DE (1) DE69504637T2 (es)
DK (1) DK0746544T3 (es)
ES (1) ES2122555T3 (es)
FI (1) FI963272A7 (es)
HU (1) HUT76133A (es)
IL (1) IL112700A0 (es)
NO (1) NO963483L (es)
NZ (1) NZ281431A (es)
WO (1) WO1995022524A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
AU6015098A (en) * 1997-02-24 1998-09-09 Cornell Research Foundation Inc. Method of screening agents as candidates for drugs or sources of drugs
US6150395A (en) 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
JP2002515484A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション 2−フェニルインドール化合物およびエストロゲン製剤からなる組成物
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
HK1044777B (en) * 1999-09-13 2006-04-13 Wyeth Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
AU2002211828A1 (en) * 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
FR2842526B1 (fr) 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
AU2004226479A1 (en) * 2003-03-27 2004-10-14 Evotec Oai Ophthalmic compositions for treating ocular hypertension
CA2562783A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
US8765488B2 (en) 2004-07-22 2014-07-01 The Board Of Trustees Of The University Of Illinois Sensors employing single-walled carbon nanotubes
WO2007062399A2 (en) * 2005-11-23 2007-05-31 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
JP5758395B2 (ja) 2009-10-15 2015-08-05 ザ チルドレンズ メディカル センター コーポレイション 疼痛を治療するためのセピアプテリンレダクターゼ阻害薬
EP2611764A4 (en) 2010-08-30 2016-12-14 Arzeda Corp FERMENTATION ROUTE FOR THE PREPARATION OF LEVULINIC ACID, LEVULINE TESTERN, VALEROLACTONE AND THEIR DERIVATIVES
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
AU2013202982C1 (en) 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
JP5997288B2 (ja) * 2012-03-05 2016-09-28 大連理工大学 ナフタレンを基本骨格とする二光子蛍光プローブ、その製造方法及びその利用方法
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
US10815247B2 (en) * 2016-12-28 2020-10-27 Promega Corporation Functionalized NANOLUC inhibitors
US20240254081A1 (en) * 2021-05-05 2024-08-01 Kare Chemical Technologies Inc. Catalytic tryptamine processes and precursors
CN116410120A (zh) * 2023-04-19 2023-07-11 四川农业大学 一种2-苯基吲哚酰胺类抗肿瘤化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1482845A (fr) * 1964-12-31 1967-06-02 Merck & Co Inc Composés de l'indol
IE66574B1 (en) * 1989-12-04 1996-01-24 Searle & Co Heterocyclic acyl aminodiol beta-amino acid derivatives
AU650261B2 (en) * 1990-03-07 1994-06-16 Rhone-Poulenc Rorer S.A. Derivatives of glycinamide, their preparation and medicaments containing them
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5496844A (en) * 1992-05-08 1996-03-05 Otsuka Pharmaceutical Factory, Inc. Indole derivatives
JPH0835029A (ja) * 1994-07-19 1996-02-06 Toyota Motor Corp 高強度高延性鋳造アルミニウム合金およびその製造方法

Also Published As

Publication number Publication date
JP3536258B2 (ja) 2004-06-07
AU1837395A (en) 1995-09-04
EP0746544A1 (en) 1996-12-11
NO963483L (no) 1996-10-22
IL112700A0 (en) 1995-05-26
NO963483D0 (no) 1996-08-21
DK0746544T3 (da) 1999-06-07
FI963272L (fi) 1996-08-21
NZ281431A (en) 1997-09-22
AU680740B2 (en) 1997-08-07
HUT76133A (en) 1997-06-30
ATE170839T1 (de) 1998-09-15
JPH09509169A (ja) 1997-09-16
KR100362864B1 (ko) 2003-04-16
DE69504637D1 (de) 1998-10-15
HU9602299D0 (en) 1996-10-28
US5877202A (en) 1999-03-02
FI963272A0 (fi) 1996-08-21
EP0746544B1 (en) 1998-09-09
CA2183731A1 (en) 1995-08-24
CA2183731C (en) 2000-03-21
WO1995022524A1 (en) 1995-08-24
DE69504637T2 (de) 1999-05-06
CN1141627A (zh) 1997-01-29
FI963272A7 (fi) 1996-08-21

Similar Documents

Publication Publication Date Title
ES2122555T3 (es) Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
PA8493801A1 (es) Moduladores del receptor glucocorticoide
AR005238A1 (es) Dihidropirimidinas y usos de las mismas, composicion farmaceutica.
HU9602668D0 (en) Progesterone antagonists useful preparing medicaments for treating dysfunctional uterine bleeding
AR005987A1 (es) Terapia combinada para la osteoporosis
ES2149971T3 (es) Derivados 5-sustituidos del acido micofenolico.
ECSP941122A (es) Derivados de 5-arilindoles
ATE359068T1 (de) Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ES2158938T3 (es) Derivados de aminoquinazolina que tienen actividad alfa-antagonistas.
PT762883E (pt) Piridilbisfosfonatos utilizaveis como agentes terapeuticos
ES8500892A1 (es) Un procedimiento para la preparacion de un nuevo derivado n-acil-peptidico.
UY26265A1 (es) Compuestos calciolíticos
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
DE69837622D1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
NO20012490D0 (no) Anvendelse av staurosporinderivater for behandling av okul¶re neovaskul¶re sykdommer
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
DE60005992D1 (de) Verwendung von ubiquinon q 10 zur vorbeugung und behandlung von postoperativen okularen pathologien
MXPA01011344A (es) El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
Kubáček Complete avulsion of skin of penis and scrotum
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ES2056337T3 (es) Utilizacion de antagonistas de receptores de tromboxano-a2 para evitar modificaciones degenerativas en el tejido penil.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746544

Country of ref document: ES